{"DataElement":{"publicId":"5040681","version":"1","preferredName":"Chronic Graft Versus Host Disease Eye Involvement NIH Consensus Response Criteria for cGVHD Severity Score","preferredDefinition":"Information related to the NIH Consensus Response Criteria for cGVHD severity of eye involvement.","longName":"5040559v1.0:5040677v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"5040559","version":"1","preferredName":"Chronic Graft Versus Host Disease Eye Involvement","preferredDefinition":"A syndrome of immunologically mediated tissue damage that may occur following an allogeneic transplant, and may affect multiple organs with manifestations similar to autoimmune diseases. The onset is usually within three years of transplantation or immunologic manipulation._The organ of sight or vision._To have a connection by participation or association or use; sharing in an activity or process.","longName":"5040557v1.0:2192548v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"5040557","version":"1","preferredName":"Chronic Graft Versus Host Disease Eye","preferredDefinition":"A syndrome of immunologically mediated tissue damage that may occur following an allogeneic transplant, and may affect multiple organs with manifestations similar to autoimmune diseases. The onset is usually within three years of transplantation or immunologic manipulation.:The organ of sight or vision.","longName":"C4981:C12401","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Graft Versus Host Disease","conceptCode":"C4981","definition":"A syndrome of immunologically mediated tissue damage that may occur following an allogeneic transplant, and may affect multiple organs with manifestations similar to autoimmune diseases. The onset is usually within three years of transplantation or immunologic manipulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Eye","conceptCode":"C12401","definition":"The organ of sight or vision.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2351E2EE-46D3-B747-E050-BB89AD430EFA","latestVersionIndicator":"Yes","beginDate":"2015-10-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-10-30","modifiedBy":"ONEDATA","dateModified":"2015-10-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2192548","version":"1","preferredName":"Involvement","preferredDefinition":"To have a connection by participation or association or use; sharing in an activity or process.","longName":"C25548","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Involvement","conceptCode":"C25548","definition":"To have a connection by participation or association or use; sharing in an activity or process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9F4C3B9-9218-0989-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-11-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-11-29","modifiedBy":"DATA_LOADER","dateModified":"2005-10-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2351E2EE-46E1-B747-E050-BB89AD430EFA","latestVersionIndicator":"Yes","beginDate":"2015-10-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-10-30","modifiedBy":"NYCHM","dateModified":"2017-01-31","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5040677","version":"1","preferredName":"Eye NIH Consensus Response Criteria for cGVHD Severity Score","preferredDefinition":"The organ of sight or vision._A tool used to assess response to therapy for chronic Graft versus Host Disease (cGVHD) based on clinical trial findings and recommended by the NIH Chronic Graft-versus-Host Disease Consensus Response Criteria Working Group. The criteria were established in 2005 (Biol Blood Marrow Transplant, 12 (2006), pp. 252-266) and revised in 2014 (Biol Blood Marrow Transplant, 21 (2015), pp. 984-999)._Used of the degree of something undesirable e.g. pain or weather; also, strictness.._A number or range of numeric values measuring performance, function, quality, or ability.","longName":"5040677v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Score 3","valueDescription":"Severe dry eye symptoms significantly affecting ADL (special eyewear to relieve pain) OR unable to work because of ocular symptoms OR loss of vision due to KCS","ValueMeaning":{"publicId":"5040678","version":"1","preferredName":"Severe dry eye symptoms significantly affecting ADL (special eyewear to relieve pain) OR unable to work because of ocular symptoms OR loss of vision due to KCS","longName":"5040678","preferredDefinition":"Severe dry eye symptoms significantly affecting ADL (special eyewear to relieve pain) OR unable to work because of ocular symptoms OR loss of vision due to KCS","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"23543715-B371-8478-E050-BB89AD434EE2","latestVersionIndicator":"Yes","beginDate":"2015-10-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-10-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"23543715-B38A-8478-E050-BB89AD434EE2","beginDate":"2015-10-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-10-30","modifiedBy":"ONEDATA","dateModified":"2015-10-30","deletedIndicator":"No"},{"value":"Score 2","valueDescription":"Moderate dry eye symptoms partially affecting ADL (requiring lubricant eye drops greater than 3 times per day or punctal plugs), without new vision impairment due to KCS","ValueMeaning":{"publicId":"5040679","version":"1","preferredName":"Moderate dry eye symptoms partially affecting ADL (requiring lubricant eye drops greater than 3 times per day or punctal plugs), without new vision impairment due to KCS","longName":"5040679","preferredDefinition":"Moderate dry eye symptoms partially affecting ADL (requiring lubricant eye drops greater than 3 times per day or punctal plugs), without new vision impairment due to KCS","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"23543715-B394-8478-E050-BB89AD434EE2","latestVersionIndicator":"Yes","beginDate":"2015-10-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-10-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"23543715-B3AD-8478-E050-BB89AD434EE2","beginDate":"2015-10-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-10-30","modifiedBy":"ONEDATA","dateModified":"2015-10-30","deletedIndicator":"No"},{"value":"Score 1","valueDescription":"Mild dry eye symptoms not affecting ADL (requirement of lubricant eye drops less than or equal to 3 times per day)","ValueMeaning":{"publicId":"5040680","version":"1","preferredName":"Mild dry eye symptoms not affecting ADL (requirement of lubricant eye drops less than or equal to 3 times per day)","longName":"5040680","preferredDefinition":"Mild dry eye symptoms not affecting ADL (requirement of lubricant eye drops less than or equal to 3 times per day)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"23543715-B3B7-8478-E050-BB89AD434EE2","latestVersionIndicator":"Yes","beginDate":"2015-10-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-10-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"23543715-B3D0-8478-E050-BB89AD434EE2","beginDate":"2015-10-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-10-30","modifiedBy":"ONEDATA","dateModified":"2015-10-30","deletedIndicator":"No"},{"value":"Score 0","valueDescription":"No symptoms","ValueMeaning":{"publicId":"3476036","version":"1","preferredName":"No symptoms","longName":"3476036","preferredDefinition":"No symptoms","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1FA8D5E-27E8-5806-E040-BB89AD43560B","latestVersionIndicator":"Yes","beginDate":"2012-06-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-06-08","modifiedBy":"KUMMEROA","dateModified":"2022-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"23543715-B3DA-8478-E050-BB89AD434EE2","beginDate":"2015-10-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-10-30","modifiedBy":"ONEDATA","dateModified":"2015-10-30","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"5042820","version":"1","preferredName":"Eye NIH Consensus Response Criteria for cGVHD Severity Score","preferredDefinition":"The organ of sight or vision.:A tool used to assess response to therapy for chronic Graft versus Host Disease (cGVHD) based on clinical trial findings and recommended by the NIH Chronic Graft-versus-Host Disease Consensus Response Criteria Working Group. The criteria were established in 2005 (Biol Blood Marrow Transplant, 12 (2006), pp. 252Â¿266) and revised in 2014 (Biol Blood Marrow Transplant, 21 (2015), pp. 984-999).:Severity; used of the degree of something undesirable e.g. pain or weather.:A number or range of numeric values measuring performance, function, quality, or ability.","longName":"C12401:C103138:C25676:C25338","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Eye","conceptCode":"C12401","definition":"The organ of sight or vision.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"NIH Consensus Response Criteria for Chronic GVHD","conceptCode":"C103138","definition":"A tool used to assess response to therapy for chronic Graft versus Host Disease (cGVHD) based on clinical trial findings and recommended by the NIH Chronic Graft-versus-Host Disease Consensus Response Criteria Working Group. The criteria were established in 2005 (Biol Blood Marrow Transplant, 12 (2006), pp. 252-266) and revised in 2014 (Biol Blood Marrow Transplant, 21 (2015), pp. 984-999).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Severity","conceptCode":"C25676","definition":"Used of the degree of something undesirable e.g. pain or weather; also, strictness.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Score","conceptCode":"C25338","definition":"A number or range of numeric values measuring performance, function, quality, or ability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"23CCF37B-99C5-FBD3-E050-BB89AD432528","latestVersionIndicator":"Yes","beginDate":"2015-11-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-11-05","modifiedBy":"ONEDATA","dateModified":"2015-11-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"23543715-B35B-8478-E050-BB89AD434EE2","latestVersionIndicator":"Yes","beginDate":"2015-10-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-10-30","modifiedBy":"NYCHM","dateModified":"2017-01-31","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"HPST_CGHD_cgvhd_eye_NIH_score","type":"NMDP_FN","context":"NHLBI"},{"name":"COG","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"What is the NIH Consensus Res","type":"Preferred Question Text","description":"What is the NIH Consensus Response Criteria for cGVHD severity of eye involvement?","url":null,"context":"NHLBI"},{"name":"Eyes score","type":"Alternate Question Text","description":"Eyes score","url":null,"context":"NHLBI"},{"name":"Eyes score","type":"Application Standard Question Text","description":"Eyes score","url":null,"context":"NHLBI"},{"name":"NIH eyes score","type":"Alternate Question Text","description":"NIH eyes score","url":null,"context":"NHLBI"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Eyes:","url":null,"context":"COG"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2353FFBF-3740-EAC9-E050-BB89AD434F78","latestVersionIndicator":"Yes","beginDate":"2015-10-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-10-30","modifiedBy":"MAESKEB","dateModified":"2022-03-31","changeDescription":".AQT added for 2100r7. 04/23/2021 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}